Vanguard Group
EIGR

Vanguard Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Vanguard Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,201
Closed -$141K – 4502
2024
Q1 		$141K Sell
28,201
-32,491
-54% -$202K ﹤0.01% 4213
2023
Q4 		$409K Sell
60,692
-4,785
-7% -$42.1K ﹤0.01% 4093
2023
Q3 		$599K Hold
65,477
– – ﹤0.01% 4002
2023
Q2 		$1.38M Sell
65,477
-6,803
-9% -$210K ﹤0.01% 3796
2023
Q1 		$1.94M Buy
72,280
+3,526
+5% +$164K ﹤0.01% 3679
2022
Q4 		$2.43M Buy
68,754
+1,068
+2% +$128K ﹤0.01% 3595
2022
Q3 		$15.3M Buy
67,686
+3,708
+6% +$911K ﹤0.01% 2747
2022
Q2 		$12.1M Buy
63,978
+7,670
+14% +$1.55M ﹤0.01% 2885
2022
Q1 		$14M Sell
56,308
-276
-0.5% -$43.6K ﹤0.01% 2970
2021
Q4 		$8.81M Buy
56,584
+33
+0.1% +$6.38K ﹤0.01% 3288
2021
Q3 		$11.3M Buy
56,551
+380
+0.7% +$90.3K ﹤0.01% 3166
2021
Q2 		$14.4M Buy
56,171
+1,913
+4% +$477K ﹤0.01% 3018
2021
Q1 		$14.4M Buy
54,258
+1,238
+2% +$390K ﹤0.01% 2956
2020
Q4 		$19.5M Buy
53,020
+8,786
+20% +$2.52M ﹤0.01% 2643
2020
Q3 		$10.8M Buy
44,234
+1,004
+2% +$312K ﹤0.01% 2747
2020
Q2 		$12.4M Buy
43,230
+814
+2% +$240K ﹤0.01% 2657
2020
Q1 		$8.65M Buy
42,416
+2,366
+6% +$754K ﹤0.01% 2682
2019
Q4 		$17.9M Buy
40,050
+2,923
+8% +$1.04M ﹤0.01% 2585
2019
Q3 		$11.4M Buy
37,127
+1,430
+4% +$465K ﹤0.01% 2746
2019
Q2 		$11.4M Buy
35,697
+10,009
+39% +$3.47M ﹤0.01% 2786
2019
Q1 		$10.8M Buy
25,688
+1,658
+7% +$665K ﹤0.01% 2786
2018
Q4 		$7.32M Buy
24,030
+9,015
+60% +$2.91M ﹤0.01% 2923
2018
Q3 		$5.41M Buy
15,015
+700
+5% +$239K ﹤0.01% 3205
2018
Q2 		$5.24M Buy
14,315
+5,036
+54% +$1.79M ﹤0.01% 3203
2018
Q1 		$2.74M Buy
9,279
+3,305
+55% +$976K ﹤0.01% 3353
2017
Q4 		$2.5M Buy
5,974
+2,737
+85% +$978K ﹤0.01% 3358
2017
Q3 		$1.07M Sell
3,237
-108
-3% -$29.4K ﹤0.01% 3576
2017
Q2 		$792K Sell
3,345
-1,591
-32% -$361K ﹤0.01% 3624
2017
Q1 		$1.7M Buy
4,936
+76
+2% +$26.2K ﹤0.01% 3429
2016
Q4 		$1.7M Sell
4,860
-22
-0.5% -$8.06K ﹤0.01% 3409
2016
Q3 		$1.96M Buy
4,882
+722
+17% +$368K ﹤0.01% 3402
2016
Q2 		$2.47M Buy
4,160
+3,022
+266% +$1.84M ﹤0.01% 3297
2016
Q1 		$573K Buy
1,138
+19
+2% +$9.46K ﹤0.01% 3753
2015
Q4 		$740K Buy
1,119
+11
+1% +$6.22K ﹤0.01% 3718
2015
Q3 		$524K Buy
1,108
+91
+9% +$48.3K ﹤0.01% 3841
2015
Q2 		$576K Buy
1,017
+366
+56% +$1.01M ﹤0.01% 3830
2015
Q1 		$5.55M Buy
651
+132
+25% +$1.15M ﹤0.01% 2944
2014
Q4 		$4.57M Buy
519
+78
+18% +$453K ﹤0.01% 2944
2014
Q3 		$2.08M Buy
441
+195
+79% +$1.03M ﹤0.01% 3246
2014
Q2 		$1.77M Buy
246
+22
+10% +$110K ﹤0.01% 3312
2014
Q1 		$1.2M Buy
+224
New +$1.06M ﹤0.01% 3397

Other funds holding EIGR

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group's EIGR Position: Q2 2024 in Review

Vanguard Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 28,201 shares — an estimated $141K sold.

Vanguard Group first reported a position in EIGR in Q1 2014 and held it in 41 quarters. The position peaked at $19.5M in Q4 2020. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

  • Vanguard Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 28,201 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $141K.
  • Vanguard Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 41 quarters.
  • Vanguard Group's Eiger BioPharmaceuticals, Inc. position peaked at $19.5M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.